Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Neuro-Oncology|February 22, 2024
Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohortYazmin Odia, Matthew D Hall, Timothy Francis Cloughesy, et al.
Neuro-Oncology|November 9, 2019
Biological activity of weekly ONC201 in adult recurrent glioblastoma patientsIsabel Arrillaga-Romany, Yazmin Odia, Varun V Prabhu, et al.
Journal of Neuro-Oncology|March 1, 2021
Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastomaMary Jane Lim-Fat, Kun Wei Song, J Bryan Iorgulescu, et al.
Neuro-Oncology|March 6, 2024
ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse gliomaIsabel Arrillaga-Romany, Andrew Lassman, Susan L McGovern, et al.
Journal of Oncology Practice|January 26, 2019
Performance of a Hospital Pathway for Patients With a New Single Brain MassIsabel Arrillaga-Romany, William T Curry, Justin T Jordan, et al.
Nature Medicine|February 24, 2023
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trialIngo K Mellinghoff, Min Lu, Patrick Y Wen, et al.
Cancers|July 12, 2025
Prognostic Features of Recurrent Midline and H3 K27M-Mutant GliomaStephen J Bagley, Yoshie Umemura, Joe S Mendez, et al.
Pageof 6